BRCA1 and breast cancer: In the unselected patient population carboplatin was not more active than docetaxel; in contrast, in patients with germline BRCA-breast cancers, carboplatin had double objective responses than docetaxel (68% vs 33%); such a therapeutic benefit was not observed with BRCA1 methylation, BRCA1 mRNA-low tumors, or a high score of a Myriad HRD assay [144].